Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

Barbara Ferrari, Carla Valsecchi, Silvia Pontiggia, Ilaria Mancini, Luca Andrea Lotta, Danijela Mikovic, Giovanna Meloni, Flora Peyvandi

Blood (2014) 124 (21): 1467.

https://doi.org/10.1182/blood.V124.21.1467.1467

Published: 2014

Journal Articles

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Giuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Federica Loscocco, Alessandro Isidori

Blood (2014) 124 (19): 3029–3031.

https://doi.org/10.1182/blood-2014-08-596668

Published: 2014

Journal Articles

Peripheral T-Cell Lymphomas (PTCL) Treated With Or Without Upfront Autologous Stem Cell Transplantation: Results Of a Retrospective Single Center Analysis

Alice Di Rocco, MD, Angelo Fama, MD, Eleonora Russo, MD, Giovanna Meloni, MD, Paolo Paesano, MD, Laura Cesini, MD, Michela Ansuinelli, MD, Saveria Capria, MD, Maurizio Martelli, MD, Robin Foá, MD

Blood (2013) 122 (21): 5548.

https://doi.org/10.1182/blood.V122.21.5548.5548

Published: 2013

Journal Articles

T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT

Norbert Claude Gorin, MD, PhD, Myriam Labopin, MD, Fabio Ciceri, Simona Piemontese, MD, William Arcese, MD, Paolo Di Bartolomeo, MD, Didier Blaise, MD, Giovanna Meloni, He Huang, MD, PhD., Depei Wu, Jia Chen, MD, Andrea Bacigalupo, MD, Attilio Olivieri, Prof., Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 3359.

https://doi.org/10.1182/blood.V122.21.3359.3359

Published: 2013

Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Blood (2013) 122 (21): 2134.

https://doi.org/10.1182/blood.V122.21.2134.2134

Published: 2013

Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD

Blood (2013) 122 (21): 829.

https://doi.org/10.1182/blood.V122.21.829.829

Published: 2013

Journal Articles

Long-Term Follow-up of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML): A Survey of 3567 Patients From the Acute Leukemia Working Party of the EBMT.

Tomasz Czerw, MD, Myriam Labopin, Norbert C. Gorin, MD, PhD, Sebastian Giebel, MD, Didier Blaise, MD, Giovanna Meloni, MD, Arnaud Pigneux, MD, PhD, Alberto Bosi, MD, Hendrik Veelken, MD PhD, Felicetto Ferrara, MD, Nicolaas Schaap, MD, PhD, Michele Baccarani, MD, Mohamad Mohty

Blood (2012) 120 (21): 3112.

https://doi.org/10.1182/blood.V120.21.3112.3112

Published: 2012

Journal Articles

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood (2011) 118 (25): 6521–6528.

https://doi.org/10.1182/blood-2011-05-351403

Published: 2011

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

Blood (2011) 118 (21): 257.

https://doi.org/10.1182/blood.V118.21.257.257

Published: 2011

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)

Roelof Willemze, MD, PhD, Petra Muus, MD, PhD, Stijn J.M. Halkes, Giovanna Meloni, MD, Stefan Suciu, Liv Meert, Jocelyne Flament, Matthias Karrasch, Marco Vignetti, Sergio Amadori, MD, Theo M. de Witte, MD, Jean-Pierre Marie, MD

Blood (2011) 118 (21): 2610.

https://doi.org/10.1182/blood.V118.21.2610.2610

Published: 2011

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance,

Blood (2011) 118 (21): 3612.

https://doi.org/10.1182/blood.V118.21.3612.3612

Published: 2011

Journal Articles

The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,

Norbert C. Gorin, MD, PhD, Myriam Labopin, MD, MS, Giovanna Meloni, MD, Arnaud Pigneux, MD, Jordi Esteve, MD, Miguel A. Sanz, MD, PhD, Alberto Bosi, William Arcese, MD, Giuseppe Milone, MD, PhD, Emmanuelle Polge, Mohamad Mohty

Blood (2011) 118 (21): 4139.

https://doi.org/10.1182/blood.V118.21.4139.4139

Published: 2011

Journal Articles

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Blood (2011) 118 (12): 3419–3425.

https://doi.org/10.1182/blood-2011-04-351924

Published: 2011

Journal Articles

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Blood (2011) 117 (12): 3294–3301.

https://doi.org/10.1182/blood-2010-08-301796

Published: 2011

Journal Articles

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Sergio Amadori, MD, Adriano Venditti, MD, Emanuele Ammatuna, MD, Alberto M. Martelli, MD, Giovanna Meloni, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Monia Lunghi, Livio Pagano, MD, Daniela Cilloni, MD, PhD, Vittorio Rizzoli, Francesco Di Raimondo, MD, Claudio Fozza, MD, Luciana Annino, MD, Alfonso Piciocchi, Edoardo La Sala, Paola Fazi, MD, Marco Vignetti, MD

Blood (2010) 116 (21): 510.

https://doi.org/10.1182/blood.V116.21.510.510

Published: 2010

Journal Articles

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood (2010) 116 (21): 2471.

https://doi.org/10.1182/blood.V116.21.2471.2471

Published: 2010

Journal Articles

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, MD, Filippo Gherlinzoni, MD, Claudio Giardini, Sadia Falcioni, Federica Loscocco, Francesca Cuberli, Marco Gobbi, MD, Armando Santoro, Barbara Sarina, Marco Rocchi, Alessandro Isidori, MD, PhD

Blood (2010) 116 (21): 31.

https://doi.org/10.1182/blood.V116.21.31.31

Published: 2010

NARROW

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Peripheral T-Cell Lymphomas (PTCL) Treated With Or Without Upfront Autologous Stem Cell Transplantation: Results Of a Retrospective Single Center Analysis

T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Long-Term Follow-up of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML): A Survey of 3567 Patients From the Acute Leukemia Working Party of the EBMT.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only